News & Events
Published On: 5/13/2021
Crohn’s & Colitis 360 Publishes Target RWE Inflammatory Bowel Disease Data
Disorders of the gastrointestinal (GI) track disrupt the lives of millions of Americans every day. Chronic inflammation of the GI tract is also known as inflammatory bowel disease, or IBD. An estimated 3 million adults in the U.S. have been diagnosed with one of the two most common types of IBD: Crohn’s disease and ulcerative colitis.1 Left untreated, IBD can lead to larger, more serious symptoms and complications. People with IBD are more likely to have other conditions including cardiovascular disease, respiratory disease, or liver disease, compared to people without an IBD diagnosis.1
Sponsored by Target RWE, TARGET-IBD (NCT03251118) is an ongoing observational, longitudinal study that gathers and analyzes real-world data (RWD) on IBD patient treatment and care over several years. The study’s RWD includes important information from patients themselves called patient-reported outcome measures (PROs) and biospecimen samples, or blood samples. TARGET-IBD’s first published manuscript detailing methodology and initial results has been recently published in the Crohn’s and Colitis Foundation’s peer-reviewed journal Crohn’s & Colitis 360 (https://doi.org/10.1093/crocol/otab023).
“IBD is a common inflammatory health condition, but data from large observational studies among diverse patients in a real-world setting is lacking,” said Julie Mallory Crawford, MD, Senior Director of Scientific & Medical Affairs, Target RWE. “TARGET-IBD gives us insight into disease severity in different care settings, treatment patterns, and clinical outcomes. Research using this valuable data can influence the way that providers care for their IBD patients in real and meaningful ways.”
The TARGET-IBD initial study results included 1,343 IBD patients enrolled over the first year from 27 academic and community sites throughout the United States. Of these, 60.1% were diagnosed with Crohn’s disease and 38.9% were diagnosed with ulcerative colitis. Baseline PROs were provided by 48.7% of the cohort and 62.6% provided a biosample.
Learn more about TARGET-IBD here.
1Centers for Disease Control and Prevention: https://www.cdc.gov/ibd/data-statistics.htm
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
07/22/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients
06/15/2021TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease
05/25/2021Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission